Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 3Melanoma 2Carcinoma, Renal Cell 2Carcinoma 2Skin Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1

Interventions

Carboplatin 30Cisplatin 23pembrolizumab 22Paclitaxel 21Pemetrexed 20Gemcitabine 10osimertinib 9durvalumab 9Nivolumab 9130-nm albumin-bound paclitaxel 8Sunitinib 7Sorafenib 7Fluorouracil 7Everolimus 7Docetaxel 7Axitinib 7Cetuximab 6epothilone B 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5volociximab 4trebananib 4reolysin 4catumaxomab 4cabozantinib 4atezolizumab 4Radiotherapy 4Ipilimumab 4vosaroxin 3liposomal doxorubicin 3lenvatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma × ProMune × Clear all
NCT00031278 2011-05-30

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

Pfizer

Phase 1/2 Completed
12 enrolled
Tumor-Agnostic

Carcinoma, Neoplasm Metastasis, Neoplasms

NCT00070642 2009-02-10

CPG 7909 Injection in Melanoma

Pfizer

Phase 2 Completed
184 enrolled
Dermatologic

Carcinoma, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡